Molecular Partners AG (NASDAQ: MOLN) has shared the results from the Phase 2a study of Ensovibep for COVID-19 patients as well as additional data from the Phase 1 study in healthy participants at the virtual European Scientific Working Group on Influenza (ESWI) Conference. The single-arm Phase 2a study included 12 patients, all of whom were COVID-19 positive, having mild to moderate symptoms.
The data from the study further confirmed Ensovibep’s potential as a valuable treatment option for COVID-19 patients. Moreover, the company is looking ahead to assess the results from the ongoing, global Phase 2-3 trial, EMPATHY. Currently, the world is facing a pandemic and with every passing day, new variants of concerns of COVID-19 are emerging which put the lives of many at risk. So, the company is striving to explore therapeutics to battle this virus as well as its future mutation
Furthermore, the company disclosed that first Ensovibep data from COVID-19 infected patients receiving 225 mg and 600 mg doses were seen to be safe and well endured. Moreover, it has been witnessed that Viral load data (qPCR) demonstrated a comparable decrease for both dose levels. In addition, the infectivity of the virus obtained through nasopharyngeal swabs was decreased to zero within 3-5 days post medication in victims with positive titers at baseline.
Moreover, the result shows that the company has witnessed the complete COVID-19 clinical symptom recovery in the study population. Hence, these results support large-scale controlled assessment of Ensovibep as a cure for mild-to-moderate COVID-19. MOLN also shared additional data from the Phase 1, randomized, double-blind, placebo-controlled single ascending dose study for safety, tolerability, and pharmacokinetics of intravenously administered Ensovibep, which showed that it was well endured with a half-life in the range of 2-3 weeks.